|
|
||||
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
MCL1 is a member of the BCL2
gene family which is involved in controlling cell viability and
immortalization. Because of their
ability to keep cells alive, these gene products can contribute to cancer. Recent data demonstrate that, in addition
to the full length MCL1 gene product, MCL1 can undergo alternative splicing
to a truncated derivative, MCL1s/deltaTM.
The shorter alternatively spliced gene product lacks sequences critical
to the viability-promoting function of MCL1, but retains a sequence which, in
the absence of the missing sequences, causes cells to die rather than
remaining alive. The next stage in
this research is to develop an approach to cause the gene product to undergo
splicing via the alternative rather than the standard pathway. This could represent a means of converting
a gene that contributes to the continuous life of the cancer cell into a
cancer killer. This technology is claimed in
the issued United States Patent No. 6,800,750. We are in the process of patenting this
technology and are seeking an industrial partner interested in its
commercialization. (Ref: J114) |
||
|
|
|
|
|
|
|
|
|
«Technology Transfer Office : Sponsored Projects : Dartmouth College |
||
|
|
||||
|
11 Rope Ferry Road #6210 |
||||
|
Hanover, NH 03755-1404 |
Phone: (603) 646-3027 |
|||
|
|
|
|
Fax: (603) 646-3670 |
|
